Renaissance in Obesity Treatment Innovation

{
  "id": "PP1162883",
  "track": "Health",
  "focus_area": null,
  "category": "Panel",
  "event_id": "PP1162883",
  "event_type": "panel",
  "format": "Panel",
  "genre": null,
  "subgenre": null,
  "name": "Renaissance in Obesity Treatment Innovation",
  "presented_by": "Real Chemistry",
  "publish_at": "2026-01-20T15:25:00.000-06:00",
  "reservable": true,
  "reservable_id": "PP1162883",
  "reserved": false,
  "date": "2026-03-17",
  "end_time": "2026-03-17T17:00:00.000-05:00",
  "start_time": "2026-03-17T16:00:00.000-05:00",
  "message": null,
  "image": null,
  "credentials": [
    {
      "name": "Music Badge",
      "type": "music"
    },
    {
      "name": "Platinum Badge",
      "type": "platinum"
    },
    {
      "name": "Innovation Badge",
      "type": "innovation"
    },
    {
      "name": "Film & TV Badge",
      "type": "filmtv"
    }
  ],
  "contributors": [
    {
      "id": 80061,
      "company": "Wave Life Sciences",
      "credential_types": [
        "filmtv",
        "innovation",
        "music"
      ],
      "entity_id": 2241367,
      "name": "Paul Bolno",
      "speaker_types": [],
      "title": " chief Executive Officer",
      "image": {
        "alt_text": "Paul Bolno",
        "credit": null,
        "url": "https://images.sxsw.com/tuDqEtlCpkYGNdl4O0nJL7CtWfU=/600x600/images.sxsw.com/48/19a614d5-b946-34ad-85c3-88135e1597aa/pcid-1630504"
      },
      "speaker_type": "Speaker",
      "details": "Dr. Paul Bolno has served as President and CEO of Wave since 2013. During his tenure as President and CEO, Paul has grown Wave into a leading RNA medicines company, overseen the development of the company’s proprietary PRISM® platform, and built a diversified pipeline of preclinical and clinical programs supported by scalable, in-house manufacturing capabilities. \n \nPaul also currently serves as Chairman of the Board of Directors to ExpressionEdits, and as Chairman of the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator (NATA) in the United Kingdom. \n \nPrior to joining Wave, he was Vice President, Worldwide Business Development—Head of Asia BD and Investments, as well as Head of Global Neuroscience BD, at GlaxoSmithKline (GSK).",
      "links": {},
      "type": "person"
    },
    {
      "id": 50505,
      "company": "Obesity Action Coalition",
      "credential_types": [
        "filmtv",
        "innovation",
        "music"
      ],
      "entity_id": 2207288,
      "name": "Joe Nadglowski",
      "speaker_types": [],
      "title": "President and CEO",
      "image": {
        "alt_text": "Joe Nadglowski",
        "credit": null,
        "url": "https://images.sxsw.com/nZzFChvT6Kh98tKFJL0DgIP_aEY=/600x600/images.sxsw.com/48/24b5feea-cde2-8cb9-07ab-cea1acfcbc32/pcid-1577109"
      },
      "speaker_type": "Speaker",
      "details": "Joseph Nadglowski is President and CEO of the Obesity Action Coalition. A frequent speaker and author on the importance of obesity awareness, Joe has more than 25 years of experience working in patient advocacy, public policy, and education. As a patient advocate who has publicly shared his own personal experience with obesity and has participated in many boards, task forces, workgroups and public testimonies, Joe was recipient of the 2012 Society for the Study of the Alimentary Tract (SSAT) Public Service Award. As part of his advocacy, he has dedicated a significant part of his work toward the recognition of weight bias, its impact on those with obesity, and our nation’s efforts to combat it.",
      "links": {},
      "type": "person"
    },
    {
      "id": 55474,
      "company": "Real Chemistry",
      "credential_types": [
        "filmtv",
        "innovation",
        "music"
      ],
      "entity_id": 2212637,
      "name": "Jennifer Paganelli",
      "speaker_types": [],
      "title": "President, Earned Media & Integration",
      "image": {
        "alt_text": "Jennifer Paganelli",
        "credit": null,
        "url": "https://images.sxsw.com/7Fuc77KyZDZe3VW8aZGhyyaYdLc=/600x600/images.sxsw.com/48/b417ed52-cea9-0ecf-019d-737570a23c62/pcid-1575239"
      },
      "speaker_type": "Speaker",
      "details": "Jennifer \"JPags\" Paganelli leads the earned media team at Real Chemistry, the largest dedicated healthcare communications and marketing firm globally. Her team of storytellers help companies across the biopharma spectrum communicate about their medicines and solutions in simple, crisp and integrated ways across media channels. An AI enthusiast and evangelist, she advises clients how to effectively communicate their stories to drive understanding, action and impact in a fragmented - and tumultuous - media environment.",
      "links": {},
      "type": "person"
    },
    {
      "id": 54221,
      "company": "Knownwell",
      "credential_types": [
        "filmtv",
        "innovation",
        "music"
      ],
      "entity_id": 2211323,
      "name": "Angela Fitch",
      "speaker_types": [],
      "title": "Chief Medical Officer",
      "image": {
        "alt_text": "Angela Fitch",
        "credit": null,
        "url": "https://images.sxsw.com/WlYrwI6SBudhzIJSUo2WsNvKwAU=/600x600/images.sxsw.com/48/2067011f-82ba-e307-dd2d-c2b87b9fc524/pcid-1587496"
      },
      "speaker_type": "Speaker",
      "details": "As Chief Medical Officer at Knownwell, Dr. Angela Fitch is a foremost expert and leader in the field of obesity medicine. She is an Assistant Professor of Medicine at Harvard University, the former Co-Director of the Massachusetts General Hospital Weight Center, a board member of the Obesity Action Coalition, and a founding member of the Massachusetts Coalition for Action on Obesity. Dr. Fitch practiced primary care for 10 years before becoming a diplomate of the American Board of Obesity Medicine in 2012, and is board-certified in obesity medicine, internal medicine, and pediatrics.",
      "links": {},
      "type": "person"
    }
  ],
  "venue": {
    "accessible": false,
    "age_policy": null,
    "floor": "2",
    "id": "V1703",
    "indoor_outdoor": "INDOOR",
    "name": "Topaz Ballroom 1-3",
    "parent_id": "V1700",
    "parent_venue_name": "The LINE",
    "venue_entry_info": null,
    "formats": null,
    "location": {
      "address": "111 E Cesar Chavez St.",
      "lat_lon": [
        30.2626651,
        -97.7436224
      ],
      "city": "Austin",
      "postal_code": "78701",
      "state": "TX",
      "name": "The LINE"
    },
    "root": {
      "accessible": null,
      "age_policy": null,
      "floor": null,
      "id": "V1700",
      "indoor_outdoor": "INDOOR",
      "name": "The LINE",
      "parent_id": null,
      "parent_venue_name": null,
      "venue_entry_info": null,
      "formats": null
    },
    "events": "[omitted 5 venue events]"
  },
  "description": "Given the need for effective obesity treatments and the limits of current GLP-1 receptor agonists, such as muscle loss, poor tolerability, and frequent dosing, a next-generation solution is essential. Ideal treatments would focus on fat loss and muscle preservation, offer strong safety and tolerability, and be dosed less frequently. Advancements in RNA medicines, growth of human genetics databases, and potential for combination therapies have opened the door for innovative new therapies and combination approaches. Explore expert insights on future treatment opportunities.",
  "experience_level": "Advanced",
  "accessibility": [],
  "accessible_venue": false,
  "add_bcl_url": false,
  "add_slido": false,
  "age_policy": null,
  "american_sign_language": false,
  "apple_url": null,
  "audio_description": false,
  "caption_url": null,
  "closed_captioned": false,
  "cpe_credit": false,
  "has_subtitles": false,
  "hash_tags": [],
  "high_sensory_experience": false,
  "live": false,
  "long_description": "Given the need for effective obesity treatments and the limits of current GLP-1 receptor agonists, such as muscle loss, poor tolerability, and frequent dosing, a next-generation solution is essential. Ideal treatments would focus on fat loss and muscle preservation, offer strong safety and tolerability, and be dosed less frequently. Advancements in RNA medicines, growth of human genetics databases, and potential for combination therapies have opened the door for innovative new therapies and combination approaches. Explore expert insights on future treatment opportunities.",
  "meeting_url": null,
  "meeting_url_live": false,
  "mentorly_url": null,
  "mobile_audio_url": null,
  "open_captioned": false,
  "playlist_tag": null,
  "rebroadcast": false,
  "recommended_ids": [],
  "search_conversions": null,
  "short_program": false,
  "slido_url": null,
  "sort": "RENAISSANCE IN OBESITY TREATMENT INNOVATION",
  "source": "Official",
  "squad_up_url": null,
  "stream_embed": null,
  "stream_id": null,
  "stream_url": null,
  "strobe_warning": false,
  "subdiscipline": null,
  "summit": null,
  "summit_display_name": null,
  "tags": [],
  "talent_attending": null,
  "title_only": false,
  "track_display_name": "Health",
  "trailer_id": null,
  "trailer_url": null,
  "video_on_demand": null,
  "vimeo_id": null,
  "vod": false,
  "xr_project_type": null,
  "youtube_id": null,
  "related_sales_client": null
}